首页> 外文期刊>International Journal of Radiation Oncology, Biology, Physics >Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients.
【24h】

Association between genetic polymorphisms in the XRCC1, XRCC3, XPD, GSTM1, GSTT1, MSH2, MLH1, MSH3, and MGMT genes and radiosensitivity in breast cancer patients.

机译:XRCC1,XRCC3,XPD,GSTM1,GSTT1,MSH2,MLH1,MSH3和MGMT基因的遗传多态性与乳腺癌患者的放射敏感性之间的关联。

获取原文
获取原文并翻译 | 示例
           

摘要

PURPOSE: Clinical radiosensitivity varies considerably among patients, and radiation-induced side effects developing in normal tissue can be therapy limiting. Some single nucleotide polymorphisms (SNPs) have been shown to correlate with hypersensitivity to radiotherapy. We conducted a prospective study of 87 female patients with breast cancer who received radiotherapy after breast surgery. We evaluated the association between acute skin reaction following radiotherapy and 11 genetic polymorphisms in DNA repair genes: XRCC1 (Arg399Gln and Arg194Trp), XRCC3 (Thr241Met), XPD (Asp312Asn and Lys751Gln), MSH2 (gIVS12-6T>C), MLH1 (Ile219Val), MSH3 (Ala1045Thr), MGMT (Leu84Phe), and in damage-detoxification GSTM1 and GSTT1 genes (allele deletion). METHODS AND MATERIALS: Individual genetic polymorphisms were determined by polymerase chain reaction and single nucleotide primer extension for single nucleotide polymorphisms or by a multiplex polymerase chain reaction assay for deletion polymorphisms. The development of severe acute skin reaction (moist desquamation or interruption of radiotherapy due to toxicity) associated with genetic polymorphisms was modeled using Cox proportional hazards, accounting for cumulative biologically effective radiation dose. RESULTS: Radiosensitivity developed in eight patients and was increased in carriers of variants XRCC3-241Met allele (hazard ratio [HR] unquantifiably high), MSH2 gIVS12-6nt-C allele (HR=53.36; 95% confidence intervals [95% CI], 3.56-798.98), and MSH3-1045Ala allele (HR unquantifiably high). Carriers of XRCC1-Arg194Trp variant allele in combination with XRCC1-Arg399Gln wild-type allele had a significant risk of radiosensitivity (HR=38.26; 95% CI, 1.19-1232.52). CONCLUSIONS: To our knowledge, this is the first report to find an association between MSH2 and MSH3 genetic variants and the development of radiosensitivity in breast cancer patients. Our findings suggest the hypothesis that mismatch repair mechanisms may be involved in cellular response to radiotherapy. Genetic polymorphisms may be promising candidates for predicting acute radiosensitivity, but further studies are necessary to confirm our findings.
机译:目的:患者之间的临床放射敏感性差异很大,在正常组织中发生的辐射诱发的副作用可能会限制治疗。一些单核苷酸多态性(SNP)已显示与对放射疗法的超敏反应相关。我们对87名乳腺癌女性患者进行了一项前瞻性研究,他们在乳腺癌手术后接受了放疗。我们评估了放疗后的急性皮肤反应与DNA修复基因中的11个遗传多态性之间的关联:XRCC1(Arg399Gln和Arg194Trp),XRCC3(Thr241Met),XPD(Asp312Asn和Lys751Gln),MSH2(gIVS12-6T> C),MLH1(Ile219Val ),MSH3(Ala1045Thr),MGMT(Leu84Phe),以及在损伤解毒GSTM1和GSTT1基因中(等位基因缺失)。方法和材料:通过聚合酶链反应和单核苷酸引物延伸确定单核苷酸多态性,或通过多重聚合酶链反应测定缺失多态性确定个体遗传多态性。与遗传多态性相关的严重急性皮肤反应(潮湿的脱皮或由于毒性导致的放疗中断)的发生,使用考克斯比例风险建模,说明了累积的生物有效辐射剂量。结果:8例患者出现了放射敏感性,并且在XRCC3-241Met等位基因变体(危险比[HR]不可定量地高),MSH2 gIVS12-6nt-C等位基因(HR = 53.36; 95%置信区间[95%CI], 3.56-798.98)和MSH3-1045Ala等位基因(无法量化的HR)。 XRCC1-Arg194Trp变异等位基因与XRCC1-Arg399Gln野生型等位基因的载体具有显着的放射敏感性风险(HR = 38.26; 95%CI,1.19-1232.52)。结论:据我们所知,这是第一份发现MSH2和MSH3基因变异与乳腺癌患者放射敏感性发展之间存在关联的报告。我们的发现提出了一个假设,即错配修复机制可能与细胞对放射疗法的反应有关。遗传多态性可能是预测急性放射敏感性的有前途的候选者,但是需要进一步的研究来证实我们的发现。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号